ORAI1 and pulmonary arterial hypertension: Because we demonstrated in the present study that the Orai1 inhibitor CM5480, or dual therapy with the standard of care for PAH, is effective in reducing PAH at both pulmonary and cardiac levels, it would be very exciting to test Auxora or similar compounds in patients with PAH.